Thiazolidinediones Pretreated Bone Marrow-Derived Mesenchymal Stem Cells As An Anti-Cancer Approach Against Mcf-7 Breast Cancer Cell Line

Breast cancer is the most prevalent type of cancer among women globally. Although treatments are currently available, most of these therapies are associated with adverse effects. For that reason, new treatment strategies utilising approved drugs may prove to be beneficial. Pioglitazone (PIO) and ros...

Full description

Saved in:

Bibliographic Details
Main Author:	Lim, Shern Kwok
Format:	Thesis
Language:	English
Published:	2022
Subjects:	R5-920 Medicine (General)
Online Access:	http://eprints.usm.my/59708/1/24%20Pages%20from%20LIM%20SHERN%20KWOK%20-%20TESIS.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-usm-ep.59708
record_format	uketd_dc
spelling	my-usm-ep.597082023-12-20T02:13:59Z Thiazolidinediones Pretreated Bone Marrow-Derived Mesenchymal Stem Cells As An Anti-Cancer Approach Against Mcf-7 Breast Cancer Cell Line 2022-09 Lim, Shern Kwok R5-920 Medicine (General) Breast cancer is the most prevalent type of cancer among women globally. Although treatments are currently available, most of these therapies are associated with adverse effects. For that reason, new treatment strategies utilising approved drugs may prove to be beneficial. Pioglitazone (PIO) and rosiglitazone (ROSI) are thiazolidinediones (TZDs) drugs that are clinically used to treat type 2 diabetes mellitus. Although PIO and ROSI have been linked to several adverse effects, there have been reports about their anti-cancer properties. For that reason, this study was conducted to improve the overall efficacy of TZDs therapy by utilising PIO and ROSI in combination to treat MCF-7 breast cancer cells. Additionally, the study also investigated the combination therapy of PIO and ROSI as a pretreatment strategy for bone marrow-derived mesenchymal stem cells (BM-MSCs) to indirectly treat MCF-7 cells via cell-cell interaction. The results revealed that PIO and ROSI when used in combination, induced higher inhibition of cell viability with lower levels of cellular lipid accumulation in MCF-7 cells at 48 and 96 hours of co-culture. Furthermore, the viability of TZDs pretreated BM-MSCs remained uninhibited for up to 96 hours and no signs of cell stress or death was observed at Day 7. 2022-09 Thesis http://eprints.usm.my/59708/ http://eprints.usm.my/59708/1/24%20Pages%20from%20LIM%20SHERN%20KWOK%20-%20TESIS.pdf application/pdf en public phd doctoral Perpustakaan Hamzah Sendut Institut Penyelidikan Perubatan Molekul
institution	Universiti Sains Malaysia
collection	USM Institutional Repository
language	English
topic	R5-920 Medicine (General)
spellingShingle	R5-920 Medicine (General) Lim, Shern Kwok Thiazolidinediones Pretreated Bone Marrow-Derived Mesenchymal Stem Cells As An Anti-Cancer Approach Against Mcf-7 Breast Cancer Cell Line
description	Breast cancer is the most prevalent type of cancer among women globally. Although treatments are currently available, most of these therapies are associated with adverse effects. For that reason, new treatment strategies utilising approved drugs may prove to be beneficial. Pioglitazone (PIO) and rosiglitazone (ROSI) are thiazolidinediones (TZDs) drugs that are clinically used to treat type 2 diabetes mellitus. Although PIO and ROSI have been linked to several adverse effects, there have been reports about their anti-cancer properties. For that reason, this study was conducted to improve the overall efficacy of TZDs therapy by utilising PIO and ROSI in combination to treat MCF-7 breast cancer cells. Additionally, the study also investigated the combination therapy of PIO and ROSI as a pretreatment strategy for bone marrow-derived mesenchymal stem cells (BM-MSCs) to indirectly treat MCF-7 cells via cell-cell interaction. The results revealed that PIO and ROSI when used in combination, induced higher inhibition of cell viability with lower levels of cellular lipid accumulation in MCF-7 cells at 48 and 96 hours of co-culture. Furthermore, the viability of TZDs pretreated BM-MSCs remained uninhibited for up to 96 hours and no signs of cell stress or death was observed at Day 7.
format	Thesis
qualification_name	Doctor of Philosophy (PhD.)
qualification_level	Doctorate
author	Lim, Shern Kwok
author_facet	Lim, Shern Kwok
author_sort	Lim, Shern Kwok
title	Thiazolidinediones Pretreated Bone Marrow-Derived Mesenchymal Stem Cells As An Anti-Cancer Approach Against Mcf-7 Breast Cancer Cell Line
title_short	Thiazolidinediones Pretreated Bone Marrow-Derived Mesenchymal Stem Cells As An Anti-Cancer Approach Against Mcf-7 Breast Cancer Cell Line
title_full	Thiazolidinediones Pretreated Bone Marrow-Derived Mesenchymal Stem Cells As An Anti-Cancer Approach Against Mcf-7 Breast Cancer Cell Line
title_fullStr	Thiazolidinediones Pretreated Bone Marrow-Derived Mesenchymal Stem Cells As An Anti-Cancer Approach Against Mcf-7 Breast Cancer Cell Line
title_full_unstemmed	Thiazolidinediones Pretreated Bone Marrow-Derived Mesenchymal Stem Cells As An Anti-Cancer Approach Against Mcf-7 Breast Cancer Cell Line
title_sort	thiazolidinediones pretreated bone marrow-derived mesenchymal stem cells as an anti-cancer approach against mcf-7 breast cancer cell line
granting_institution	Perpustakaan Hamzah Sendut
granting_department	Institut Penyelidikan Perubatan Molekul
publishDate	2022
url	http://eprints.usm.my/59708/1/24%20Pages%20from%20LIM%20SHERN%20KWOK%20-%20TESIS.pdf
_version_	1794024040160034816

Thiazolidinediones Pretreated Bone Marrow-Derived Mesenchymal Stem Cells As An Anti-Cancer Approach Against Mcf-7 Breast Cancer Cell Line

Similar Items